Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Biodistribution of an Autologous Bone Marrow-Derived Mononuclear Cell Infusion into Renal Arteries in Patients with Focal Segmental Glomerulosclerosis: A Phase 1 Study.
Botelho BF, Barreira AL, Filippo MG, Asensi KD, Faccioli LAP, Dos Santos Salgado AB, de Salles EF, Marques CEC, Silva PL, Dos Santos Goldenberg RC, Maiolino A, Gutfilen B, de Souza SAL, Junior ML, Morales MM. Botelho BF, et al. Among authors: maiolino a. Stem Cells Int. 2024 Jul 9;2024:2385568. doi: 10.1155/2024/2385568. eCollection 2024. Stem Cells Int. 2024. PMID: 39015674 Free PMC article.
Adipose Tissue-Derived Stromal/Stem Cells Transplantation with Cholecalciferol Supplementation in Recent-Onset Type 1 Diabetes Patients: Twelve Months Follow-Up.
Dantas JR, Araujo DB, Silva KR, Souto DL, Pereira MFC, Raggio LR, Claudio-da Silva C, Couri CE, Maiolino A, Rebellato CLK, Daga DR, Senegaglia AC, Brofman PRS, Baptista LS, Oliveira JEP, Zajdenverg L, Rodacki M. Dantas JR, et al. Among authors: maiolino a. Horm Metab Res. 2023 Aug;55(8):536-545. doi: 10.1055/a-2094-1039. Epub 2023 May 16. Horm Metab Res. 2023. PMID: 37192655
Evaluation of type 1 diabetes' partial clinical remission after three years of heterologous adipose tissue derived stromal/stem cells transplantation associated with vitamin D supplementation.
Leão IS, Dantas JR, Araújo DB, Ramos MEN, Silva KR, Batista LS, Pereira MFC, Luiz RR, da Silva CC, Maiolino A, Rebelatto CLK, Daga DR, Senegaglia AC, Brofman PRS, de Oliveira JEP, Zajdenverg L, Rodacki M. Leão IS, et al. Among authors: maiolino a. Diabetol Metab Syndr. 2024 May 24;16(1):114. doi: 10.1186/s13098-024-01302-2. Diabetol Metab Syndr. 2024. PMID: 38790009 Free PMC article.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, Li J, Capra M, Maiolino A, Pappa V, Chraniuk D, Osipov I, Leleu X, Low M, Matsumoto M, Sule N, Li M, McKeown A, He W, Bright S, Currie B, Perera S, Boyle J, Roy-Ghanta S, Opalinska J, Weisel K. Dimopoulos MA, et al. Among authors: maiolino a. Lancet Haematol. 2023 Oct;10(10):e801-e812. doi: 10.1016/S2352-3026(23)00243-0. Lancet Haematol. 2023. PMID: 37793771 Clinical Trial.
Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era.
Hungria V, Pinto Neto JV, Garibaldi PMM, Jansen AM, Filho RJPM, Pericole FV, Sanku G, Maiolino A. Hungria V, et al. Among authors: maiolino a. Clin Lymphoma Myeloma Leuk. 2024 Dec 12:S2152-2650(24)02442-X. doi: 10.1016/j.clml.2024.12.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39809660
Health care Systems as Determinants of Outcomes in Multiple Myeloma: Final Results from the Latin American MYLACRE Study.
Hungria VTM, Gaiolla RD, Galvez K, Remaggi G, Schutz N, Bittencourt RI, Maiolino A, Quintero-Vega GE, Cugliari MS, Braga WMT, Villarim CC, Crusoé EQ, Enrico AII MD, Caeiro G, Bigonha JG, Moura FL, Figueroa Emiliani J Dr, Sossa-Melo C, Lombana M, Pei H, Fernandez M, Saes J, Trufelli DC. Hungria VTM, et al. Among authors: maiolino a. Blood Adv. 2024 Dec 10:bloodadvances.2024013838. doi: 10.1182/bloodadvances.2024013838. Online ahead of print. Blood Adv. 2024. PMID: 39657126
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
The Brazilian association of hematology, hemotherapy, and cell therapy (ABHH) and its absolute commitment to ethics and absence of conflicts of interest.
de Souza CA, Rego EM, Ribeiro GN, Magalhães SMM, da Silva CAR, Passos LNDM, Covas DT, Tavares RS, Hungria VTM, Crusoé EQ, Marques JFC Jr, Chiattone CS, Langhi D Junior, Neto JVP, Laforga VP, Maiolino A. de Souza CA, et al. Among authors: maiolino a. Hematol Transfus Cell Ther. 2024 Jul-Sep;46(3):219-220. doi: 10.1016/j.htct.2024.05.003. Epub 2024 May 26. Hematol Transfus Cell Ther. 2024. PMID: 38821779 Free PMC article. No abstract available.
120 results